Browsing Tag
Acute Graft Versus Host Disease
1 post
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.